Takashi Shimada
Net worth: 181 487 $ as of 31/05/2026
Net worth: 181 487 $ as of 31/05/2026
Takashi Shimada is currently Chairman at KMT Hepatech, Inc. since 2017, Chairman at PhoenixBio USA Corp.
since 2018, and President & Representative Director at PhoenixBio Co., Ltd. since 2018.
Formerly, Mr. Shimada was Director & Administration Manager at Institute of Immunology Co., Ltd.
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
PHOENIXBIO CO., LTD. 1.68% | 30/09/2025 | 68,300 ( 1.68% ) | 181 487 $ | 31/05/2026 |
| Companies | Position | Start |
|---|---|---|
| PHOENIXBIO CO., LTD. | President | 28/06/2018 |
PhoenixBio USA Corp.
PhoenixBio USA Corp. Miscellaneous Commercial ServicesCommercial Services Develops technologies for mass propagation of human cells into laboratory animals | Chairman | 01/06/2018 |
KMT Hepatech, Inc.
KMT Hepatech, Inc. Miscellaneous Commercial ServicesCommercial Services Develops methods to support human liver cells in a mouse that allows support of infections | Chairman | 01/12/2017 |
| Companies | Position | End |
|---|---|---|
Institute of Immunology Co., Ltd.
Institute of Immunology Co., Ltd. Medical SpecialtiesHealth Technology Develops and produces diagnostic reagents and monoclonal antibodies | Chief Administrative Officer | - |
Active
Inactive
Listed companies
Private companies
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
| Private companies | 4 |
|---|---|
KMT Hepatech, Inc.
KMT Hepatech, Inc. Miscellaneous Commercial ServicesCommercial Services Develops methods to support human liver cells in a mouse that allows support of infections | Commercial Services |
Institute of Immunology Co., Ltd.
Institute of Immunology Co., Ltd. Medical SpecialtiesHealth Technology Develops and produces diagnostic reagents and monoclonal antibodies | Health Technology |
PhoenixBio Co., Ltd.
PhoenixBio Co., Ltd. Miscellaneous Commercial ServicesCommercial Services Develops technologies for mass propagation of human cells into laboratory animals | Commercial Services |
PhoenixBio USA Corp.
PhoenixBio USA Corp. Miscellaneous Commercial ServicesCommercial Services Develops technologies for mass propagation of human cells into laboratory animals | Commercial Services |
Select your edition
All financial news and data tailored to specific country editions